This research investigates whether the diabetes drug dapagliflozin (DAPA) can be repurposed to treat metabolic dysfunction-associated steatotic liver disease (MASLD). Using laboratory models, it examines fat accumulation and NHE1 ion channel function, aiming to develop a cost-effective treatment for two closely linked metabolic diseases with one existing medicine.

Tuberculosis remains deadly despite relying on decades-old antibiotics. This research uses computational methods to identify immune response similarities between TB and other diseases, enabling drug repurposing. By borrowing already approved treatments, this approach aims to restore immune balance, combat drug resistance, and accelerate the development of new TB therapies.